Neri, Paola <br/><br/>
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.  [electronic resource] 

 -  Blood  Dec 2011 
 - 6368-79 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-06-363911  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>BRCA1 Protein--genetics<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Cell Line, Tumor<br/>Cells, Cultured<br/>DNA Repair--drug effects<br/>Enzyme Inhibitors--administration & dosage<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Mice<br/>Mice, SCID<br/>Multiple Myeloma--drug therapy<br/>Poly(ADP-ribose) Polymerase Inhibitors<br/>Proteasome Endopeptidase Complex<br/>Proteasome Inhibitors<br/>Pyrazines--administration & dosage<br/>RNA, Messenger--metabolism<br/>Rad51 Recombinase--genetics<br/>Survival Analysis<br/>Xenograft Model Antitumor Assays